Nothing said here yet.
to join the conversation.
| RAAB MICHAELPresident & CEO | Sell | 19,178 | $74.0K | Fri, Aug 21 |
| Bishop John ESee Remarks | Sell | 17,281 | $66.7K | Fri, Aug 21 |
| RAAB MICHAELPresident & CEO | Sell | 15,976 | $61.6K | Fri, Aug 21 |
| RAAB MICHAELPresident & CEO | Sell | 15,009 | $57.9K | Fri, Aug 21 |
| Brady James ParkerChief Human Resources Officer | Sell | 13,160 | $50.8K | Fri, Aug 21 |
| RAAB MICHAELPresident & CEO | Sell | 8,411 | $32.4K | Fri, Aug 21 |
| Williams Laura AChief Patient Officer | Sell | 3,486 | $13.4K | Fri, Aug 21 |
| Foster Eric DuaneChief Commercial Officer | Sell | 3,389 | $13.1K | Fri, Aug 21 |
| Kelliher MikeChief Business Officer | Sell | 3,104 | $12.0K | Fri, Aug 21 |
| Williams Laura AChief Patient Officer | Sell | 3,089 | $11.9K | Fri, Aug 21 |
| Reilly Joseph JamesSee Remarks | Sell | 2,872 | $11.1K | Fri, Aug 21 |
| Kelliher MikeChief Business Officer | Sell | 2,652 | $10.2K | Fri, Aug 21 |
Faruqi Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages...
Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes
Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the YearWALTHAM, Mass., Sept.
Ardelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said at a Morgan Stanley event.
WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc.
Ardelyx (ARDX) recently cut its 2026 IBSRELA revenue guidance to a range of $350 million to $370 million, down from $410 million to $430 million, citing tougher payer utilization-management hurdles that slowed new patient starts.
Ardelyx guided investors to $410-$430 million in 2026 IBSRELA revenue and reiterated that range on April 30, 2026. On August 6, the Company cut it to $350-$370 million -- and ARDX fell 17.86% the next session. NEW YORK, Aug.